Cargando…
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
Antibodies have proven their high value in antitumor therapy over the last two decades. They are currently being used as the first-choice to treat some of the most frequent metastatic cancers, like HER2(+) breast cancers or colorectal cancers, currently treated with trastuzumab (Herceptin) and bevac...
Autores principales: | Corraliza-Gorjón, Isabel, Somovilla-Crespo, Beatriz, Santamaria, Silvia, Garcia-Sanz, Jose A., Kremer, Leonor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742572/ https://www.ncbi.nlm.nih.gov/pubmed/29312320 http://dx.doi.org/10.3389/fimmu.2017.01804 |
Ejemplares similares
-
92R Monoclonal Antibody Inhibits Human CCR9(+) Leukemia Cells Growth in NSG Mice Xenografts
por: Somovilla-Crespo, Beatriz, et al.
Publicado: (2018) -
Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9(+) tumors
por: Santamaria, Silvia, et al.
Publicado: (2022) -
Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible?
por: Santamaria, Silvia, et al.
Publicado: (2017) -
Editorial: Is the Recent Burst of Therapeutic Anti-tumor Antibodies the Tip of an Iceberg?
por: Kremer, Leonor, et al.
Publicado: (2018) -
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2018)